Clinical trials: Adenovirus
Healthy
A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults
The purpose of this study is to explore the dose-response relationship of immune responses induced by different dose levels of an Ad26.RSV.preF based vaccine (Cohort 1) and to assess the safety and reactogenicity of different…
- Trial name
- NCT04453202
- Testing
- RSV Vaccine
- Where
- 9 sites in United States
- Volunteers
- 459 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Solid Tumor
A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors
This is a Phase 1 open-label study to evaluate the safety, tolerability, and pharmacokinetics of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) at dose of 5×10∧9VP、5×10∧10VP、5×10∧11VP in Patients With…
- Trial name
- NCT06215846
- Testing
- BioTTT001 injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Prostate Cancer
Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer
Phase I single-blinded, randomized, placebo-controlled trial evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of single injections of ascending doses of investigational drug product Mobilan (М-VM3)…
- Trial name
- NCT02654938
- Testing
- Mobilan (M-VM3)
- Where
- 6 sites in Russia
- Volunteers
- 32 people
- Sponsor
- Panacela Labs LLC
Recurrent Head and Neck Cancer
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer
Primary Objective: The primary objective of the study is to evaluate the safety of repeat administration of a dose level of Ad/PNP plus fludarabine phosphate (F-araAMP) which demonstrated anti-tumor activity in patients with…
- Trial name
- NCT03754933
- Testing
- Ad/PNP, Fludarabine Phosphate
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- GeoVax, Inc.
Anthrax Infection
A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines
The purpose of this study is to evaluate 2 vaccine candidates against anthrax compared to the positive (vaccine) control as studied in normal healthy volunteers.
- Trial name
- NCT01979406
- Testing
- AVA, Ad4-PA-1, Ad4-PA-GPI-1
- Where
- 4 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer
The purpose of this study is to determine the safety and tolerability of three intratumoral injections of VCN-01 combined with Abraxane®/gemcitabine, and to determine the recommended phase II dose of VCN-01 combined with…
- Trial name
- NCT02045589
- Testing
- VCN-01, Gemcitabine, Abraxane®
- Where
- 3 sites in Spain
- Volunteers
- 8 people
- Sponsor
- Theriva Biologics SL
COVID-19
COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers
This is a phase 1b, open-label study in adult healthy subjects. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of the hAd5-S-Fusion+N-ETSD vaccine and select a dose for future studies.
- Trial name
- NCT04591717
- Testing
- hAd5-S-Fusion+N-ETSD vaccine
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
Severe Haemophilia A
Gene Therapy Study in Severe Haemophilia A Patients (270-201)
This study is being conducted by BioMarin Pharmaceutical Inc. as an open label, dose escalation study in order to determine the safety and efficacy of valoctocogene roxaparvovec (an Adenovirus-Associated Virus based gene therapy…
- Trial name
- NCT02576795
- Testing
- valoctocogene roxaparvovec
- Where
- 5 sites in United Kingdom
- Volunteers
- 15 people
- Sponsor
- BioMarin Pharmaceutical
COVID-19
A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups.
The study is a single-center, randomized and double-blinded trial to evaluate the immunobridging between different manufacture scales, lot-to-lot consistency of the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5…
- Trial name
- NCT04916886
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml
- Where
- China
- Volunteers
- 2,021 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Adenoviral Conjunctivitis
Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo
The purpose of this study is to determine if an investigational treatment is effective compared with placebo and PVP-Iodine in the treatment of adults and children with adenoviral conjunctivitis.
- Trial name
- NCT02998541
- Testing
- SHP640, PVP-I 0.6%
- Where
- 130 sites in United States, Australia and 14 more
- Volunteers
- 219 people
- Sponsor
- Shire
Hepatitis B Virus (HBV)
Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) in Chronic Hepatitis B Patients
Hepatitis B virus (HBV) infection is a worldwide health problem. It has been proved that the persistence of HBV is associated with the failure to stimulate an efficient HBV-specific immune response.
- Trial name
- NCT04168333
- Testing
- T101 Group
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tasly Tianjin Biopharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients
This is a Phase 1/2, multi-center, open-label, dose-escalation trial of Ad-MAGEA3 and MG1-MAGEA3 in combination with pembrolizumab in patients with Non-Small Cell Lung Cancer who have completed a first standard therapy with at…
- Trial name
- NCT02879760
- Testing
- Ad-MAGEA3, MG1-MAGEA3, Pembrolizumab
- Where
- 6 sites in Canada
- Volunteers
- 16 people
- Sponsor
- Turnstone Biologics, Corp.
Chronic Hepatitis B
Non-investigational Study to Evaluate Adenovirus Serotype 5 (Ad5) Neutralizing Antibodies (nAb) in Patients With Chronic Hepatitis B Virus (HBV) Mono-infection
Objectives: Primary Objective: To identify and preselect patients with chronic HBV mono infection, who are undetectable for anti-Ad5 nAb, currently being treated with nucleo(t)sides, for participation in the TG1050.02 Phase1/1b…
- Trial name
- NCT02355951
- Testing
- blood draw
- Where
- 11 sites in Canada, France and 1 more
- Volunteers
- 166 people
- Sponsor
- Transgene
Viral Infection
ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus
The subjects eligible for this trial have a type of blood cell cancer, other blood disease or a genetic disease for which they will receive a stem cell transplant.
- Trial name
- ARMS (NCT01570283)
- Testing
- Multivirus-specific T cells Dose Level 1, Multivirus-specific T cells Dose Level 2, Multivirus-specific T cells Dose Level 3
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- AlloVir
Mucopolysaccharidosis Type III A, Sanfilippo Disease Type A
Intracerebral Gene Therapy for Sanfilippo Type A Syndrome
The clinical trial P1-SAF-301 is an open-label, single arm, monocentric, phase I/II clinical study evaluating the tolerance and the safety of intracerebral administration of adeno-associated viral vector serotype 10 carrying the…
- Trial name
- NCT01474343
- Testing
- SAF-301
- Where
- 2 sites in France
- Volunteers
- 4 people
- Sponsor
- LYSOGENE
Ebola Viral Disease
A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of 3 vaccination schedules of Ad26.ZEBOV and MVA-BN-Filo administered intramuscularly (IM) as 2-dose heterologous regimens.
- Trial name
- NCT02416453
- Testing
- MVA-BN-Filo, Ad26.ZEBOV
- Where
- 11 sites in France, United Kingdom
- Volunteers
- 423 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
COVID - 19, SARS CoV-2
Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19
This is a Phase 1a, single-country, single-centre, single-blinded, COV2 vaccine formulation randomized trial designed to investigate and compare the safety and immunogenicity of two COV2 vaccine formulations.
- Trial name
- NCT07416539
- Testing
- COVID-19 Vaccines
- Where
- Finland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Rokote Laboratories Finland Oy
Hepatitis C
Study of a Novel Therapeutic Vaccine for Hepatitis C Virus
HCV002TV is a Phase I study to ascertain the safety and immunogenicity of a novel vaccine against Hepatitis C virus (HCV) in chronically infected patients.
- Trial name
- NCT01094873
- Testing
- AdCh3NSmut, Ad6NSmut
- Where
- 2 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- ReiThera Srl
Liver Metastases, Liver Metastasis Colon Cancer
DNX-2440 for Resectable Colorectal Liver Metastasis
The purpose of this study is to test an experimental oncolytic adenovirus called DNX-2440 in patients with resectable multifocal (≥ 2 lesions) liver metastasis, who are scheduled to have curative-intent liver resection surgery.
- Conditions
- Liver Metastases, Liver Metastasis Colon Cancer, Colorectal Cancer, Breast Cancer
- Trial name
- NCT04714983
- Testing
- DNX-2440
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- DNAtrix, Inc.
Covid19
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
VXA-CoV2-1 is a non-replicating Ad5 vector adjuvanted oral tableted vaccine being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection.
- Trial name
- NCT04563702
- Testing
- VXA-CoV2-1
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Vaxart